1 / 4

SYNERGY PCI A Subset analysis of the SYNERGY trial

SYNERGY PCI A Subset analysis of the SYNERGY trial. 4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin. Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose.

pippa
Télécharger la présentation

SYNERGY PCI A Subset analysis of the SYNERGY trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SYNERGY PCIA Subset analysis of the SYNERGY trial 4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50 to 70 seconds Primary Endpoint: Death/MI at 30 days

  2. SYNERGY PCI Death / MI by intent-to-treat analysis at 30 days Death MI Death or MI P=NS P=NS % P=NS

  3. SYNERGY PCI Bleeding in the intent-to-treat analysis at 30 days TIMI minor TIMI major GUSTO severe % P<0.05

  4. SYNERGY PCI • Among high-risk ACS patients undergoing PCI, the rate of death/MI at 30 days was not significantly different between patients treated with enoxaparin or unfractionated heparin. • Primary endpoint data for PCI patients is consistent with primary SYNERGY trial • As in primary SYNERGY trial, enoxaparin was associated with an increase in TIMI major bleeding

More Related